Australian Clinical Labs Ltd
ASX:ACL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (9.6), the stock would be worth AU$3.14 (65% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.8 | AU$1.91 |
0%
|
| 3-Year Average | 9.6 | AU$3.14 |
+65%
|
| 5-Year Average | 8.6 | AU$2.82 |
+47%
|
| Industry Average | 38.4 | AU$12.59 |
+559%
|
| Country Average | 18.1 | AU$5.93 |
+210%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Australian Clinical Labs Ltd
ASX:ACL
|
365.2m AUD | 5.8 | 13.9 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
106.6B USD | 12.6 | 60.3 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
71B EUR | 12.6 | 14.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
77B USD | 0 | 12.9 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.3B EUR | -24.7 | 18.1 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.5B EUR | 13.9 | 22.8 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21B USD | 23.3 | 20.6 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.1B USD | 631 | 24.1 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.6B EUR | 6.5 | 10.8 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | 65.8 | -26.2 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 6 | 14 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 12.5 |
| Median | 18.1 |
| 70th Percentile | 35.6 |
| Max | 5 049.1 |
Other Multiples
Australian Clinical Labs Ltd
Glance View
Australian Clinical Labs Ltd. provides pathology services. The company is headquartered in Melbourne, Victoria and currently employs 2,794 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in private hospital pathology businesses in regions of Western Australia, Victoria, South Australia and the Northern Territory. Its brands include Australian Clinical Labs, SunDoctors, Helix Pathology, Southern Sun, BeFunctional Labs and Gribbles Veterinary Pathology. The Australian Clinical Labs provides pathology in Australia, servicing clinicians, patients, hospitals, commercial clients and public organizations. The SunDoctors offers diagnosis and treatment of skin cancer. The Helix Pathology delivers specialized histopathology and cytology testing services. The Southern Sun is the skin cancer lab and the commercial lab in Australia. The BeFunctional Labs assists practitioners in the diagnosis, treatment and management of patients by providing functional pathology tests. The Gribbles Veterinary Pathology provides animal health professionals with pathology service.
